Effect of CYP2D6 on risperidone pharmacokinetics and extrapyramidal symptoms in healthy volunteers: Results from a pharmacogenetic clinical trial

Pharmacogenomics

Volumn 15, Issue 1, 2014, Pages 17-28

  Gassó, Patricia ^a,b,c   Mas, Sergi ^a,b,c   Papagianni, Katerina ^a   Ferrando, Eva ^a   De Bobadilla, Ramón Fernández ^d   Arnaiz, Joan Albert ^a,b,e   Bioque, Miquel ^b,c,e   Bernardo, Miquel ^a,b,c,d   Lafuente, Amalia ^a,b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

CYP2D6; Extrapyramidal symptoms; Pharmacogenetics; Randomized clinical trial; Risperidone

Indexed keywords

CYTOCHROME P450 2D6; PALIPERIDONE; PLACEBO; RISPERIDONE;

ACTIMETRY; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYP2D6 GENE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOGENETICS; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RISPERIDONE;

EID: 84890504332     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.204     Document Type: Article

References (35)

1. Ravyn D, Ravyn V, Lowney R, Nasrallah HA. CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr. Res. 149, 1-14 (2013).
2. Yasui-Furukori N, Hidestrand M, Spina E et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab. Dispos. 29, 1263-1268 (2001). (Pubitemid 32896574)
3. Kang RH, Jung SM, Kim KA et al. Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. J. Clin. Psychopharmacol. 29, 272-277 (2009).
4. Llerena A, Berecz R, Dorado P et al. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J. Psychopharmacol. 18, 189-193 (2004). (Pubitemid 38954905)
5. de Leon J, Susce MT, Pan RM et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J. Clin. Psychiatry 66, 15-27 (2005).
6. Troost PW, Lahuis BE, Hermans MH et al. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J. Clin. Psychopharmacol. 27, 52-57 (2007). (Pubitemid 46105764)
7. Barteček R, Juřica J, Zrůstová J et al. Relevance of CYP2D6 variability in first-episode schizophrenia patients treated with risperidone. Neuro Endocrinol. Lett. 33, 236-244 (2012).
8. Kobylecki CJ, Jakobsen KD, Hansen T et al. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 59, 222-226 (2009).
9. Locatelli I, Kastelic M, Koprivsek J et al. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. Eur. J. Pharm. Sci. 41, 289-298 (2010).
10. Tonda ME, Guthrie SK. Treatment of acute neuroleptic-induced movement disorders. Pharmacotherapy 14, 543-560 (1994). (Pubitemid 24299954)
11. Kapur S, Zipursky RB, Remington G. Clinical and theorical implications of 5-HT2 and D2 receptor occupancy of clozapine olanzapine and risperidone in schizophrenia. Am. J. Psychiatry 156, 286-293 (1999). (Pubitemid 29077120)
12. Mas S, Bernardo M, Gassó P et al. A functional variant provided further evidence for the association of ARVCF with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153, 1052-1059 (2010).
13. Mas S, Gassò P, Alvarez S, Parellada E, Bernardo M, Lafuente A. Intuitive pharmacogenetics: spontaneous risperidone dosage is related to CYP2D6, CYP3A5 and ABCB1 genotypes. Pharmacogenomics J. 12, 255-259 (2012).
14. Crescenti A, Mas S, Gasso P, Baiget M, Bernardo M, Lafuente A. Simultaneous genotyping of CYP2D6 3,4,5 and 6 polymorphisms in a Spanish population through multiplex long-PCR and minisequencing multiplex single base extension (SBE) analysis. Clin. Exp. Pharmacol. Physiol. 34, 992-997 (2007). (Pubitemid 47274547)
15. Corripio I, Ferreira A, Portella MJ et al. The role of striatal dopamine D2 receptors in the occurrence of extrapyramidal side effects: iodine-123-iodobenzamide single photon emission computed tomography study. Psychiatry Res. 201, 73-77 (2012).
16. Simpson GM, Angus JW. A rating scale for extra-pyramidal side effects. Acta Psychiatr. Scand. Suppl. 212, 11-19 (1970).
17. Barnes TR. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154, 672-676 (1989). (Pubitemid 19154942)
18. Middelkoop HA, van Dam EM, Smilde-van den Doel DA, van Dijk G. 45-hour continuous quintuple-site actimetry: relations between trunk and limb movements and effects of circadian sleep-wake rhythmicity. Psychophysiology 34, 199-203 (1997). (Pubitemid 27143354)
19. Ventura J, Lukoff D, Nuechterlein KH. Appendix 1: Brief Psychiatric Rating Scale Expanded Version (4.0) scales, anchor points, and administration manual. Int. J. Meth. Psychiatr. Res. 3, 227-243 (1993).
20. Andreasen NC. Modified Scale for the Assessment of Negative Symptoms (SANS). University of Iowa Press, IA, USA (1984).
21. Jaeger J, Bitter I, Czobor P, Volavka J. The measurement of subjective experience in schizophrenia: the Subjective Deficit Syndrome Scale. Compr. Psychiatry 31, 216-226 (1990). (Pubitemid 20169114)
22. Bond AJ, James DC, Lader MH. Sedative effects on physiological and psychological measures in anxious patients. Psychol. Med. 4, 374-380 (1974).
23. Xiang Q, Zhao X, Zhou Y, Duan JL, Cui YM. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J. Clin. Pharmacol. 50, 659-666 (2010).
24. Jovanović N, Božina N, Lovrić M, Medved V, Jakovljević M, Peleš AM. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur. J. Clin. Pharmacol. 66, 1109-1117 (2010).
25. Scordo MG, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl ML. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl.) 147, 300-305 (1999). (Pubitemid 30010551)
26. Ono S, Mihara K, Suzuki A et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl.) 162, 50-54 (2002). (Pubitemid 34639556)
27. Mihara K, Kondo T, Yasui-Furukori N et al. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther. Drug Monit. 25, 287-293 (2003). (Pubitemid 36638171)
28. Riedel M, Schwarz MJ, Strassnig M et al. Risperidone plasma levels, clinical response and side-effects. Eur. Arch. Psychiatry Clin. Neurosci. 255, 261-268 (2005). (Pubitemid 41187035)
29. Vermeulen A, Piotrovsky V, Ludwig EA. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder. J. Pharmacokinet. Pharmacodyn. 34, 183-206 (2007). (Pubitemid 46536257)
30. Wang L, Yu L, Zhang AP et al. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J. Psychopharmacol. 21, 837-842 (2007). (Pubitemid 350029187)
31. Novalbos J, López-Rodríguez R, Román M, Gallego-Sandín S, Ochoa D, Abad-Santos F. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J. Clin. Psychopharmacol. 30, 504-511 (2010).
32. Walther S, Horn H, Koschorke P, Müller TJ, Strik W. Increased motor activity in cycloid psychosis compared with schizophrenia. World J. Biol. Psychiatry 10, 746-751 (2009).
33. Kiang M, Daskalakis ZJ, Christensen BK, Remington G, Kapur S. Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects. J. Psychiatry Neurosci. 28, 293-299 (2003). (Pubitemid 37153437)
34. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol. 7, 415-419 (2004). (Pubitemid 39648071)
35. APSEP clinical trial.http://clinicaltrials.gov/ct2/show/NCT01259973